- Home
- GYRE vs ECO Comparison
GYRE vs ECO Comparison
Compare GYRE & ECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- ECO
- Stock Information
- Founded
- GYRE 2002
- ECO 2018
- Country
- GYRE United States
- ECO Greece
- Employees
- GYRE N/A
- ECO N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- ECO
- Sector
- GYRE Health Care
- ECO
- Exchange
- GYRE Nasdaq
- ECO Nasdaq
- Market Cap
- GYRE 897.1M
- ECO 878.3M
- IPO Year
- GYRE N/A
- ECO N/A
- Fundamental
- Price
- GYRE $7.90
- ECO $30.72
- Analyst Decision
- GYRE Strong Buy
- ECO Strong Buy
- Analyst Count
- GYRE 1
- ECO 2
- Target Price
- GYRE $18.00
- ECO $34.50
- AVG Volume (30 Days)
- GYRE 96.3K
- ECO 127.6K
- Earning Date
- GYRE 11-12-2025
- ECO 11-07-2025
- Dividend Yield
- GYRE N/A
- ECO 5.92%
- EPS Growth
- GYRE N/A
- ECO N/A
- EPS
- GYRE 0.02
- ECO 2.09
- Revenue
- GYRE $102,189,000.00
- ECO $344,213,634.00
- Revenue This Year
- GYRE $18.39
- ECO N/A
- Revenue Next Year
- GYRE $48.26
- ECO $11.01
- P/E Ratio
- GYRE $469.46
- ECO $14.73
- Revenue Growth
- GYRE N/A
- ECO N/A
- 52 Week Low
- GYRE $6.11
- ECO $17.91
- 52 Week High
- GYRE $19.00
- ECO $35.64
- Technical
- Relative Strength Index (RSI)
- GYRE 51.30
- ECO 74.56
- Support Level
- GYRE $7.55
- ECO $27.87
- Resistance Level
- GYRE $8.56
- ECO $29.40
- Average True Range (ATR)
- GYRE 0.51
- ECO 0.75
- MACD
- GYRE -0.01
- ECO 0.20
- Stochastic Oscillator
- GYRE 57.14
- ECO 92.42
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.